Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
| Autor: | Mauriac, L., Pippen, J.E., Quaresma Albano, J., Gertler, S.Z., Osborne, C.K. |
|---|---|
| Zdroj: | In European Journal of Cancer June 2003 39(9):1228-1233 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect